PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML

被引：0
|
作者：
Kadia, T. [1 ]
Cortes, J. [1 ]
Borthakur, G. [1 ]
Jabbour, E. [1 ]
Daver, N. [1 ]
Pemmaraju, N. [1 ]
Verstovsek, S. [1 ]
Burger, J. [1 ]
Ferrajoli, A. [1 ]
Wierda, W. [1 ]
Konopleva, M. [1 ]
DiNardo, C. [1 ]
Jain, N. [1 ]
Brandt, M. [1 ]
Tuttle, C. [1 ]
Wang, X. [1 ]
Ravandi, F. [1 ]
Garcia-Manero, G. [1 ]
Kantarjian, H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P187
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [1] Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Ferrajoli, Alessandra
    Verstovsek, Srdan
    Ravandi, Farhad
    Pemmaraju, Naveen
    Daver, Naval Guastad
    Konopleva, Marina
    Wang, Xuemei
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Daver, Naval
    Jabbour, Elias
    Pemmaraju, Naveen
    Verstovsek, Srdan
    Burger, Jan A.
    Wierda, William G.
    Konopleva, Marina
    DiNardo, Courtney D.
    Jain, Nitin
    Brandt, Mark
    Tuttle, Carla
    Wang, Xuemei
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2014, 124 (21)
  • [3] Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Jain, Preetesh
    Jabbour, Elias
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Faderl, Stefan
    Ravandi, Farhad
    Konopleva, Marina
    Tuttle, Carla
    Brandt, Mark
    Wang, Xuemei
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [4] Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML).
    Cashen, Amanda
    Schiller, Gary J.
    Larsen, Julie S.
    Cullen, Michael T., Jr.
    DiPersio, John F.
    BLOOD, 2006, 108 (11) : 561A - 562A
  • [5] Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Sasaki, Koji
    Daver, Naval
    Issa, Ghayas C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Jain, Nitin
    Bhalla, Kapil N.
    Jabbour, Elias J.
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Rausch, Caitlin R.
    Malla, Rashmi
    Marek, Kelly
    Brandt, Mark
    Popat, Uday R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [6] Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Cortes, Jorge E.
    Jabbour, Elias J.
    Daver, Naval
    Pemmaraju, Naveen
    Ravandi, Farhad
    Jain, Nitin
    Verstovsek, Srdan
    DiNardo, Courtney
    Alvarado, Yesid
    Ferrajoli, Alessandra
    Burger, Jan A.
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Konopleva, Marina
    Estrov, Zeev
    Wierda, William
    Brandt, Mark
    Fitch, Tina
    Borthakur, Gautam
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [7] Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients:: First results of a multicenter phase II study.
    Lübbert, M
    Rüter, B
    Schmid, M
    Knipp, S
    Germing, U
    Dobbelstein, C
    Eimermacher, H
    Deschler, B
    Claus, R
    Schlenk, R
    Ganser, A
    Döhner, H
    Schmoor, C
    Henss, H
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [8] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kadia, Tapan M.
    Reville, Patrick K.
    Wang, Xuemei
    Rausch, Caitlin R.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval G. G.
    DiNardo, Courtney D. D.
    Sasaki, Koji
    Issa, Ghayas C. C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J. J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N. N.
    Jabbour, Elias
    Takahashi, Koichi
    Malla, Rashmi
    Quagliato, Kelly
    Kanagal-Shamanna, Rashmi
    Popat, Uday R. R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina Y. Y.
    Ravandi, Farhad
    Kantarjian, Hagop M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
  • [10] Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine
    Faderl, Stefan
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Huang, Xuelin
    Jabbour, Elias
    Kadia, Tapan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Feliu, Jennie
    Schroeder, Heather
    Kwari, Monica
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 152 - 152
12345